経口生物利用可能なサイクリンA/B RxL阻害剤:E2F高およびG1-Sチェックポイントに妥協した癌を標的とするマクロサイクリックペプチドの新種の最適化
Justin A Shapiro1, Nathan J Dupper1, Breena Fraga-Walton1
1Circle Pharma, 169 Harbor Way, South San Francisco, California 94080, United States.
Journal of medicinal chemistry
|February 21, 2026
まとめ
研究者らは,小細胞肺がん (SCLC) の治療のために,サイクリンA/Bを標的とした口服可能なマクロサイクリックペプチドを開発した. これらの化合物は選択的に癌細胞を殺し,臨床前モデルで腫瘍の回帰を示しており,現在第1相臨床試験中の主要候補である.
科学分野:
- 分子生物学は分子生物学である.
- 腫瘍学 腫瘍学
- 薬用化学 薬用化学について
背景:
- サイクリンAとBは,サイクリン依存キナーゼ (CDK) を活性化することによって,細胞サイクル進行を調節する.
- RxLモチーフを含むサイクリン-水性パッチ (HP) 相互作用は,基板と調節体を募集するために重要である.
- ターゲティングサイクリンA/Bは,E2F活性が高いがんに対する潜在的な治療戦略を提供します.
研究 の 目的:
- シクリンA/Bを阻害するマクロサイクリックペプチドを最適化して,薬剤のような性質と経口生物利用性を改善します.
- 小細胞肺がん (SCLC) モデルにおける経口投与のための鉛化合物の発見.
- サイクリンA/B阻害剤の臨床評価を進めるために.
主な方法:
- サイクリンA/B水性パッチ (HP) を標的にするマクロサイクリックペプチドの設計と合成.
- 鉛化合物の経口生物利用性と薬剤のような性質の最適化.
- 経口投与後のSCLCの細胞由来異種移植 (CDX) モデルにおける腫瘍回帰の評価.
主要な成果:
- サイクリンAおよびBに結合する受動的に透過するマクロサイクリックペプチドの識別.HP.
- E2F活性が高い細胞で選択的に癌細胞を殺すことの実証.
- 経口投与によるSCLC CDXモデルの腫瘍回帰を示す最適化された鉛化合物の発見.
- サイクリンA/B阻害の臨床試験第1相への成功.
結論:
- サイクリンA/Bを標的とした最適化されたマクロサイクリックペプチドは,有望な抗癌活性と経口生物利用性を示しています.
- 鉛化合物は,臨床前のSCLCモデルで有効性を実証し,その臨床的可能性を支持しています.
- サイクリンA/B阻害は,現在臨床試験中のSCLCの有効な治療方法です.
関連する概念動画
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Positive Regulator Molecules
7.0K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.0K
Positive Regulator Molecules
136.7K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
136.7K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
M-Cdk Drives Transition Into Mitosis
6.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K


